Floatz logo

cc-5013

Myeloproliferative Neoplasm

Medical College of WisconsinPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

46 Active assets in the Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Decitabine
Jacqueline Garcia, MD
Phase 2BB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BB
Azacitidine
Prelude Therapeutics
Phase 2BB
Cladribine
M.D. Anderson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →